Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary sclerosing cholangitis.

L M Alba1, P Angulo, K D Lindor

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic Foundation Rochester, MN 55905, USA.

Minerva Gastroenterologica E Dietologica
|February 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?

Alimentary pharmacology & therapeutics·2018
Same author

Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.

Alimentary pharmacology & therapeutics·2018
Same author

Editorial: Betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease.

Alimentary pharmacology & therapeutics·2015
Same author

An update on primary sclerosing cholangitis:from pathogenesis to treatment.

Minerva gastroenterologica e dietologica·2013
Same author

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.

Alimentary pharmacology & therapeutics·2013
Same author

Interactions between chronic liver disease and inflammatory bowel disease.

Inflammatory bowel diseases·2013
Same journal

Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration.

Minerva gastroenterologica e dietologica·2021
Same journal

Diagnostic accuracy of computerized tomography (CT) angiography in detecting non-variceal gastrointestinal bleeding (NVGIB): a sistematic review.

Minerva gastroenterologica e dietologica·2020
Same journal

Helicobacter pylori and non-alcoholic fatty liver disease.

Minerva gastroenterologica e dietologica·2020
Same journal

Hypertriglyceridemic pancreatitis.

Minerva gastroenterologica e dietologica·2020
Same journal

Effectiveness of percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis.

Minerva gastroenterologica e dietologica·2020
Same journal

Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores.

Minerva gastroenterologica e dietologica·2020
See all related articles

Primary sclerosing cholangitis (PSC) is a chronic bile duct disease often linked to inflammatory bowel disease. Further research is needed to understand its autoimmune origins and develop effective treatments beyond liver transplantation.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Immunology

Background:

  • Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown cause.
  • It is frequently associated with inflammatory bowel disease and characterized by bile duct inflammation and fibrosis.
  • Current understanding suggests autoimmunity and genetic predisposition play roles, but pathogenesis remains incomplete.

Purpose of the Study:

  • To review the current understanding of PSC pathogenesis.
  • To highlight clinical manifestations and complications of PSC.
  • To discuss current and future therapeutic strategies for PSC.

Main Methods:

  • Literature review of recent studies on PSC.
  • Analysis of clinical manifestations and disease progression.

Related Experiment Videos

  • Evaluation of current treatment options and future research directions.

    • Main Results:

    • PSC presents with fatigue, pruritus, jaundice, and abdominal pain, but is increasingly diagnosed in asymptomatic individuals.
    • The disease progresses to biliary cirrhosis, portal hypertension, and hepatic failure.
    • Complications include cholangitis, biliary strictures, colorectal cancer, and cholangiocarcinoma.

    Conclusions:

    • No definitive medical therapy exists to halt PSC progression; ursodeoxycholic acid is under evaluation.
    • Understanding PSC pathogenesis is crucial for developing new treatments.
    • Liver transplantation is the only option to improve survival in end-stage PSC, with prognostic models aiding transplant timing.